Evolving Paradigms in STS: Perspectives With Shreyaskumar R. Patel and Jonathan C. Trent, MD
Shreyaskumar R. Patel, MD and Jonathan C. Trent, MD discussed the use of trabectedin and the future of the treatment paradigms in soft tissue sarcoma.
The Impact of WHO's Tumor Reclassifications on Brain Cancer Care
Arie Perry, MD, chief of neuropathology at UCSF in San Francisco, California, discusses what oncologists should be aware of when diagnosing patients after these reclassifications, how it could change pathology, as well as a discussion on hereditary tumors.
Expert Discusses Treating Patients With NRAS-Mutated Colorectal Cancer
Maria Ignez Braghiroli, MD, discusses a study that parsed out patients with solely NRAS-mutated colorectal cancer, what the current treatment paradigm is for these patients, and how the mutation status of a patient with colorectal cancer may affect their treatment.
Nab-Paclitaxel Beneficial Over Paclitaxel In Breast Cancer Subsets
Sibylle Loibl, MD, PhD, discusses the most recent subanalysis of the GeparSepto trial, how the drugs match up in terms of toxicities, and a separate set of data looking at patients with breast cancer who are also pregnant.
Lapatinib May Aid In Control Of Brain Metastases In HER2-Positive Breast Cancer
Julia White, MD, discusses the upcoming phase II trial, the toxicities associated with the treatment, and the potential for control of these metastases. According to White, the trial is still accruing its 143 patients.
Expert on Benefit of Dual HER-2 Directed Therapy, MA17R Trial
In an interview with <em>Targeted Oncology</em>, Frankie Holmes, MD, discusses HER2-directed therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta).
XMT-1536 as a Game-Changer for NSCLC and Ovarian Cancer
The antibody drug conjugate XMT-1536 could change the treatment paradigm for both non-small cell lung cancer (NSCLC) and ovarian cancer, according to Donald Bergstrom, MD, PhD.
Controversies And Advancements In Liver Cancer
Michael Choti, MD, discusses the importance of biomarkers when it comes to choosing treatments, which treatments to choose for certain patients with GI cancer, and the improvement of systemic therapy.
New Drugs, Immuno-Oncology Advances Gastric Cancer Treatment Paradigm
Immuno-oncology and the classification of subtypes of gastric cancer could greatly advance treatment efficacy and variation, according to Manish A. Shah, MD.
Expert Discusses Recent Developments in Polycythemia Vera
In an interview with <em>Targeted Oncology</em>, Srdan Verstovsek, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses recent developments in polycythemia vera.
New Surgical Techniques, Personalized Medicine on Horizon for Glioblastoma
Despite some surgical advancements in recurrent glioblastoma, significant progress and a move toward a more personalized approach is still needed, said Jennifer Moliterno Gunel, MD.
Disease Biology Key to Effective Treatment in Triple Negative Breast Cancer
To more effectively treat patients with triple negative breast cancer (TNBC), a greater understanding of the disease must first be obtained, said Angela DeMichele, MD, professor of medicine and epidemiology, breast cancer oncologist, University of Pennsylvania.
Homologous Recombination Deficiency May Be Linked to Bladder Cancer Recurrences
Cell cycle progression (CCP) and homologous recombination deficiency (HRD) may be linked to bladder cancer recurrences and pathologic complete responses, according to Hristos Kaimakliotis, MD.
Preventive Surgery in Ovarian Cancer Depends on Several Variables, Says Markman
Undergoing surgery to prevent ovarian cancer should depend on familial history, as well as age, according to Maurie Markman, MD.
PEGPH20 as a Potential Breakthrough in Pancreatic Adenocarcinoma
The upcoming HALO 3013 is the first-ever biomarker-driven trial in pancreatic adenocarcinoma, and could potentially change the treatment paradigm for the disease.
New Subtypes of GI Cancer Beginning to Surface
The differentiation between squamous and adenocarcinomas in GI cancer could revolutionize the disease's treatment paradigm, according to John Marshall, MD.
Data on Quality of Life in Patients With Pancreatic Cancer Begins to Emerge
A multicenter trial taking place in Germany seeks to quantify the quality of life for patients with metastatic pancreatic cancer undergoing a combination of nab-paclitaxel and gemcitabine.
Immunotherapy on the Horizon in Gastric Cancer
While the utilization of immunotherapy in gastric cancer may not be as clear cut as it is in melanoma or lung cancer, Zev Wainberg, MD, illustrates some trials where the therapy type is breaking through.
Biomarkers Still Critical Challenge in Immunotherapy
The search for effective biomarkers is still one of the biggest challenges in cancer, said Janice M. Mehnert, MD.
The Role of Immunotherapy and Oncolytic Viruses in the Future of Cancer Treatment
Immunotherapy may not phase out surgery and chemotherapy as standards of care in cancer, but oncolytic viruses may usher in a new age of treatment.
Expert Highlights Numerous Benefits of Atezolizumab in Bladder Cancer
Atezolizumab proves to be non-toxic and shows major survival advantage in patients with metastatic urothelial bladder cancer.
Several Trials Examining Radiotherapy in Hodgkin Lymphoma Move to Phase II
Data from the phase I HD7 through HD11 trials proves promising enough to move on to phase II.
Cessation of TKI Treatment in Patients with CML May be Beneficial, Says Expert
Two-thirds of patients with chronic myeloid leukemia who ceased to receive the TKI treatment imatinib did not relapse after six months, according to Johan Richter, MD, PhD.
Blinatumomab Potentially Poised to be Next Standard of Care in Acute Lymphoblastic Leukemia, Says Expert
Blinatumomab almost doubles the overall survival of patients with relapsed/refractory acute lymphoblastic leukemia, according to Max Topp, MD.
Expert Discusses Challenges in Pancreatic Cancer, Potential of Immunotherapy
Understanding the roadblocks of immunotherapy in patients with newly diagnosed, metastatic pancreas cancer could provide oncologists with a new therapeutic tool to add to their armamentarium, according to Eileen O'Reilly, MD.
Nivolumab Explored in Anal Cancer
A recent phase II trial examining nivolumab (Opdivo) in patients with anal cancer seeks to explore the biological makeup, and uncover potential biomarkers in anal cancer.
The Role of Early Tumor Shrinkage in Metastatic Colorectal Cancer
Early tumor shrinkage is linked to overall survival and could be a stronger surrogate marker than progression-free survival in metastatic colorectal cancer.
Challenges of Pre-Operative Chemotherapy in Esophageal and GE-Junction Cancers
Pre-operative chemotherapy alone in esophageal cancer may not be the best choice for patients undergoing resection.
Durvalumab Shows Promise for Urothelial Bladder Cancer
The PD-L1 inhibitor durvalumab demonstrated an objective response rate of 46% for patients with high PD-L1-expressing advanced urothelial bladder cancer.
Expert Examines PD-L1 as Biomarker in Lung Cancer
While PD-L1 has been perceived as an important biomarker in the realm of lung cancer, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, says it still has a long way to go.
2 Clarke Drive Cranbury, NJ 08512